Evanston-based biopharmaceutical company Aptinyx Inc. Thursday said a drug it is studying to treat patients with painful diabetic peripheral neuropathy failed a recent clinical study.The drug, NYX-2925, did not achieve statistically significant separation from a placebo on the study’s primary endpoint, which assessed the change from baseline in average daily pain on the numeric rating scale, the company said.
Related posts
-
Polar plungers hit the pool for Special Olympics in Fox Lake
About 150 participants jumped into a frigid pool during Sunday’s Fox Lake Polar Plunge for Special... -
Ex-employee admits to stealing more than $100,000 from Geneva dance school
A former employee of a Geneva dance studio has been sentenced to probation after admitting guilt... -
Aurora primary Tuesday to narrow the field for mayoral election
A primary election Tuesday will decide what two people can run for Aurora mayor in April.